Friday, July 31, 2026

2026 YG Global Audition: How to Join and Shine in Asia’s Biggest Talent Search

YG Entertainment launches its first global audition in two years, expanding talent search across multiple countries from July to December.

Shinsegae Food Launches Nutritious Samgyetang in the U.S.: What to Expect?

Shinsegae Food is entering the U.S. market with its Ginseng Chicken Soup, aiming to expand its global convenience food business.

South Korea’s Foreign Minister Urges North Korea to Resume Dialogue at ARF

South Korea's Foreign Minister urges North Korea to engage in dialogue during ASEAN meetings, emphasizing regional security and cooperation.

Tag: cancer

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Unlocking Cell Growth: How LARS1 Protein Transforms Nutritional Signals into Cancer Treatment Insights

KAIST researchers unveil how cells sense nutrients, linking it to mTORC1 activation, paving the way for targeted cancer therapies.

Radiopharmaceuticals Revolution: How Novartis’s 1.4 Billion USD Investment Transforms Cancer Treatment in South Korea

A 140 billion KRW investment by Novartis aims to enhance the radioactive pharmaceutical industry, focusing on precision medicine and Theranostics.

Blood Test Alone May Predict Chemotherapy Response and Prognosis in Lymphoma Patients

South Korean researchers discover a mechanism reducing rituximab's effectiveness in DLBCL and propose a predictive blood biomarker.

Foreign Health Insurance Enrollment Surges 28%: What This Means for Asia’s Healthcare Landscape

Foreign health insurance in the U.S. surged 28% to 1.68 million subscribers, showing a surplus of 2.8 trillion KRW over three years.

NGeneBio Expands Blood Cancer Diagnostic Panel Supply to Seoul National University Bundang Hospital

NGeneBio expands its blood cancer diagnostic panel supply, achieving strong growth in South Korea and international markets.

How Celltrion’s Truxima Dominates the U.S. Rituximab Market: A 4-Month Winning Streak

Celltrion's Truxima leads the U.S. rituximab market for four months, gaining FDA interchangeability status, boosting growth prospects.

2026 Breakthrough in Medical Imaging: Discover How New Polymer ICG Improves Fluorescence Stability

A study improves near-infrared dye stability for tumor imaging, enhancing medical diagnostics by reducing fluorescence loss during procedures.

Unlocking the Mystery: How Anti-CTLA-4 Boosts B Cell Response Against Brain Tumors

Researchers reveal that B cells, not just T cells, are crucial for the success of immune checkpoint inhibitors in treating glioblastoma.

HLB’s Rivoceranib Drug Approval: What the FDA’s VAI Classification Means for Liver Cancer Treatment

HLB's Rivoceranib facility received a VAI classification from the FDA, indicating compliance with GMP standards, aiding drug approval progress.

HLB’s Liver Cancer Drug: FDA’s VAI Conclusion Sparks Hope for Approval

HLB's Rivoceranib facility passed FDA inspection, receiving VAI classification, moving towards new liver cancer drug approval.

Smoking Raises Fatty Liver Risk by Up to 1.5 Times Among Young Adults

Young adult smokers face a higher risk of fatty liver disease, with significant findings on its impact regardless of obesity or alcohol consumption.

[Exclusive] HLB’s Liver Cancer Drug Clears Camrelizumab CMC Review, but Hengrui Manufacturing Facility Becomes New Hurdle

HLB's liver cancer drug approval faces delays due to FDA findings at Hengrui's facility, despite resolution of previous issues.

Belvarafenib: The Promising New Targeted Cancer Drug for NRAS Mutant Melanoma

Hanmi Pharmaceutical presents Belvarafenib's phase 2 trial for NRAS mutant melanoma at KCA 2026, targeting unmet medical needs.

Korea’s First CAR-T Therapy Clears Initial Reimbursement Hurdle, With First Prescriptions Expected in October

South Korea's first CAR-T therapy, Rimkato, moves closer to national health insurance reimbursement, with commercialization expected by year-end.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.